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Purpose: The modified Glasgow Prognostic Score (mGPS) consisting of serum 
C-reactive protein and albumin levels, shows significant prognostic value in sever-
al types of tumors. We evaluated the prognostic significance of mGPS in 285 pa-
tients with diffuse large B cell lymphoma (DLBCL), retrospectively. Materials 
and Methods: According to mGPS classification, 204 patients (71.5%) had an 
mGPS of 0, 57 (20%) had an mGPS of 1, and 24 (8.5%) had an mGPS of 2. Re-
sults: Our study found that high mGPS were associated with poor prognostic fac-
tors including older age, extranodal involvement, advanced disease stage, unfavor-
able International Prognostic Index scores, and the presence of B symptoms. The 
complete response (CR) rate after 3 cycles of R-CHOP chemotherapy was higher 
in patients with mGPS of 0 (53.8%) compared to those with mGPS of 1 (33.3%) 
or 2 (25.0%) (p=0.001). Patients with mGPS of 0 had significantly better overall 
survival (OS) than those with mGPS=1 and those with mGPS=2 (p=0.036). Multi-
variate analyses revealed that the GPS score was a prognostic factor for the CR 
rate of 3 cycle R-CHOP therapy (p=0.044) as well as OS (p=0.037). Conclusion: 
mGPS can be considered a potential prognostic factor that may predict early re-
sponses to R-CHOP therapy in DLBCL patients.
Key Words:   Modified Glasgow Prognostic Score, diffuse large B cell lymphoma, 
prognostic factor
INTRODUCTION
The most significant advance in the treatment of diffuse large B-cell lymphoma 
(DLBCL) over the past 15 years has been the addition of rituximab to standard 
CHOP chemotherapy (R-CHOP).1,2 Before the rituximab era, the International 
Prognostic Index (IPI) was a widely accepted prognostic factor for patients with ag-
gressive non-Hodgkin’s lymphoma (NHL) that were treated with the CHOP regi-
men, consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone, 
or CHOP-like regimens.3,4 Because the R-CHOP regimen has become the current 
standard treatment for patients with DLBCL, the question of whether, and to what 
extent, prognostic factors change with novel treatment strategies has been debated.5
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CRP, albumin levels and IPI group (scored from 0 to 5 by 
age >60, stage ≥3, ECOG PS ≥2, LDH higher than upper 
limit of normal range and number of extranodal involve-
ment ≥2) were collected and incorporated as potential prog-
nostic factors in various analyses. We also collected data re-
garding comorbidities such as chronic hepatitis, diabetes, 
cardiovascular disease, and hypertension that are associated 
with CRP elevation.15,16
Allocation of mGPS
Baseline serum CRP and albumin levels were collected by 
clinical routine measurements using nephelometric assays 
and bromocresol green dye-binding methods with an auto-
analyzer according to the manufacturer’s instructions. The 
mGPS was constructed, using CRP and albumin, as fol-
lows: patients with both elevated CRP (≥10 mg/L) and low 
albumin (<3.5 g/dL) levels were allocated a score of 2, pa-
tients with only CRP elevated (≥10 mg/L) were allocated a 
score of 1, and those with normal CRP levels were allocat-
ed a score of 0. The rationale and basis of the mGPS has 
been previously described.9
Treatment and response criteria
The standard R-CHOP regimen consists of rituximab (375 
mg/m2) intravenously (IV), cyclophosphamide (750 mg/m2) 
IV, doxorubicin (50 mg/m2) IV, and vincristine (1.4 mg/m2; 
maximum dose of 2.0 mg) IV on day 1, followed by oral 
prednisolone (100 mg) on days 1 to 5. All patients received 
greater than 3 cycles of R-CHOP therapy. Eleven patients 
with stage I disease were treated with 3 cycles of R-CHOP 
followed by involved-field radiotherapy. In some patients 
that were not in complete remission (CR) after the last cy-
cle of chemotherapy, residual masses were irradiated 4 
weeks after completion of chemotherapy. Some patients 
(n=206) received 6 or 8 cycles of R-CHOP therapy. 
Response was evaluated after at least 3 cycles of R-CHOP 
therapy. Evaluations were performed based on the follow-
ing criteria. CR was defined as the disappearance of all 
clinical evidence of lymphoma, with no persistent disease-
related symptoms. Partial response (PR) was defined as a 
decrease >50% in the sum of the products of the two lon-
gest diameters of all measurable lesions. Non-measurable 
lesions had to decrease by at least 50%. Progressive disease 
(PD) was defined as any increase >50% in the sum of the 
diameters of any measurable lesions or the appearance of 
new lesions. Stable disease (SD) was considered to be any 
condition intermediate between PR and PD.17
It is evident that inflammatory cells have powerful effects 
on tumor development. In neoplastic process, these cells are 
powerful tumor promoters, producing an attractive environ-
ment for tumor growth, facilitating genomic instability, and 
promoting angiogenesis.6,7 In particular, the systemic inflam-
matory response, evidenced by C-reactive protein (CRP), has 
an important role in the progression of a variety of tumors.8 
The measurement of the systemic inflammatory response has 
subsequently been refined using a selective combination of 
CRP and albumin, and is termed the modified Glasgow 
Prognostic Score (mGPS). This score has been shown to 
have prognostic value in various tumors.9,10 Inflammatory cy-
tokines play important roles in the pathogenesis of lympho-
ma and may reflect underlying biological processes, includ-
ing tumor-host interactions with prognostic information.11,12 
Recently, the prognostic significance of CRP in recurrent or 
refractory aggressive lymphoma as a response predictor of 
salvage therapy has been reported.13 It also has been shown 
that the mGPS is independent prognostic factor of survival 
outcome in extranodal natural killer (NK)/T-cell lympho-
ma, nasal type.14 To our knowledge, there are no reports on 
the significance of mGPS in DLBCL.
In this study, we evaluated the significance of mGPS as a 
predictor of response and survival in DLBCL patients treat-
ed with the R-CHOP regimen.
MATERIALS AND METHODS
Patients
We reviewed the clinical records of 285 newly-diagnosed 
DLBCL patients treated with the R-CHOP regimen at the 
Division of Hematology, Yonsei University Severance Hos-
pital between October 2005 and 2010. None of the patients 
were infected with human immunodeficiency virus. Base-
line serum CRP and albumin levels were available for all 
patients. Patients with clinical evidence of acute infection or 
chronic active inflammatory disease were excluded. Age 
(≤60 years vs. >60 years), Eastern Cooperative Oncology 
Group performance status (ECOG PS, ≤1 vs. ≥2), B symp-
toms (present vs. absent), Ann Arbor clinical stage (≤2 vs. 
≥3), extranodal involvement (numbers ≤1 vs. ≥2), bulky dis-
ease (largest diameter of the disease ≥10 cm, present vs. ab-
sent), bone marrow (BM) involvement at diagnosis (present 
vs. absent), serum lactate dehydrogenase (LDH) levels 
(normal vs. elevated), absolute lymphocyte count (ALC) at 
diagnosis (<1.0×109/L vs. ≥1.0×109/L), baseline serum 
Yundeok Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 6   November 20141570
cant differences.
RESULTS
 
Patients characteristics
The study population included 285 patients (156 males and 
129 females) with a median age of 58 years (range, 21‒87 
years). The characteristics of the patients are summarized in 
Table 1. We classified the patients according to baseline se-
rum CRP and albumin levels as mGPS=0 (n=204), mGPS= 
1 (n=57), and mGPS=2 (n=24) as described previously.9 
Older age (>60 years) (p=0.003) and B symptoms (p<0.001) 
were more frequent in patients with GPS=2 compared to 
other patients. Patients with a higher GPS had significantly 
lower ALC (p=0.036), more than one extranodal (EN) site 
involvement (p=0.014), advanced disease stage, (p<0.001), 
and higher IPI risk group (p<0.001). Other characteristics 
showed no significant differences across groups with differ-
Statistical analyses
The statistical package SPSS 20.0 (SPSS Inc., Chicago, IL, 
USA) was used for all analyses. Differences between the 
groups were assessed using χ2-tests in cases of discrete vari-
ables or t-tests in cases of continuous variables. χ2-tests 
were used to analyze the relationship between mGPS and 
response rates. Overall survival (OS) was measured from 
the date of diagnosis to the date of death (from any cause) 
or to the last follow-up. Progression-free survival (PFS) 
was defined as the interval from the date of diagnosis to the 
date the patient experienced recurrence/progression of dis-
ease, death from any cause, or last follow-up. Univariate 
analyses of the effects of patient characteristics at diagnosis 
(including mGPS) upon survival were estimated using the 
Kaplan-Meier method, and compared using log-rank tests. 
Cox proportional-hazards regression analyses were used to 
evaluate multivariate analyses. All factors associated with a 
p value <0.50 by univariate analyses were forced in multi-
variate analyses. p values <0.05 denoted statistically signifi-
Table 1. Patient Characteristics According to mGPS Level
Characteristics
Total 
n=285 (%)
mGPS=0
n=204 (%)
mGPS=1
n=57 (%)
mGPS=2
n=24 (%)
p value
Age, median (yrs) 58 (21‒87) 0.003
    ≤60 159 (56.0) 127 (62.3) 22 (39.3) 10 (41.7)
    >60 125 (44.0)   77 (37.7) 34 (60.7) 14 (58.3)
Sex (male) 156 (54.7) 108 (52.9) 37 (64.9) 11 (45.8) 0.181
ECOG PS 0.087
    0‒1 263 (92.3) 191 (93.6) 52 (91.2) 20 (83.3)
    ≥2 22 (7.7) 14 (6.4) 5 (8.8)   4 (16.7)
B symptoms (yes)*   45 (15.8)   25 (12.3)   8 (14.0) 12 (50.0) <0.001
EN sites ≥2 173 (61.1) 116 (57.4) 37 (64.9) 20 (83.3) 0.014
BM involvement 26 (9.4) 15 (7.5)   6 (10.9)   5 (22.7) 0.061
Bulky disease (≥10 cm)   72 (25.3)   45 (22.1) 17 (29.8) 10 (41.7) 0.076
ALC <1.0×109/L 146 (51.2) 102 (50.0) 23 (40.4) 21 (87.5) 0.036
LDH >245 U/L 201 (71.5) 144 (71.6) 34 (60.7) 23 (95.8) 0.244
Ann Arbor stage <0.001
    I/II 149 (52.3) 121 (59.3) 23 (40.4)   5 (20.8)
    III/IV 136 (47.7)   83 (40.7) 34 (59.6) 19 (79.2)
IPI score <0.001
    0‒1 123 (43.5) 103 (50.7) 19 (33.9) 1 (4.2)
    2‒5 161 (56.5) 102 (49.3) 37 (66.1) 23 (95.8)
Comorbidities
    Chronic hepatitis B   31 (11.4)   24 (12.4) 4 (7.1)   3 (13.6) 0.663
    HTN   69 (24.2)   39 (19.1) 21 (36.8)   9 (37.5) 0.006
    DM   33 (11.6) 20 (9.8)   9 (16.1)   4 (16.7) 0.151
    CVA   4 (1.4)   3 (1.5) 1 (1.8) 0 0.707
mGPS, modified Glasgow Prognostic Score; ECOG PS, Eastern Cooperative Oncology Group Performance status; EN, extranodal; BM, bone marrow; ALC, 
absolute lymphocyte count; LDH, lactate dehydrogenase; IPI, International Prognostic Index; HTN, hypertension; DM, diabetes mellitus; CVA, cardiovascu-
lar disease.
*B symptoms, presence of at least one of the following: night sweats, weight loss >10% over 6 months, and recurrent fever >38.3°C.
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(p<0.001), advanced stage (p<0.001), elevated LDH (p= 
0.001), baseline ALC <1.0×109/L (p=0.039), and mGPS=2 
(p<0.001) significantly influenced CR rate after 3 cycles of 
R-CHOP therapy (Table 3). In multivariate analyses, older 
age [hazard ratio (HR)=0.470; 95% confidence interval (CI), 
0.262 to 0.842; p=0.011], advanced stage (HR=0.387; 95% 
CI, 0.209 to 0.719; p=0.003), bulky disease (HR=0.417; 95% 
CI, 0.209 to 0.833; p=0.013), and mGPS ≥2 (HR=0.612; 
95% CI, 0.380 to 0.988; p=0.044) retained independent ad-
verse prognostic values for the CR rate to 3 cycles of R-
CHOP therapy (Table 4).
Some patients (n=207, 72.6%) received greater than 5 cy-
cles of R-CHOP therapy. Response after 6 or more cycles of 
R-CHOP therapy was evaluated in 197 patients. The CR 
rates (58.8%) in patients with mGPS=2 tend to be lower than 
in those with mGPS=0 and mGPS=1 (84.1% vs. 68.9%), al-
though it was not statistically significant (p=0.168) (Table 2).
Overall survival
The median follow-up period was not achieved in all pa-
tients and 60 patients (21.1%) died. Fig. 1 shows Kaplan-
Meier curves for OS stratified according to mGPS. The 
5-year OS rates for patients with mGPS=0, mGPS=1, and 
mGPS=2 were 80.9%, 74.1%, and 54.7%, respectively 
(p=0.001) (Fig. 1A, Table 3). Patients with mGPS=0 had a 
significantly better OS than those with mGPS=2 (p<0.001). 
Moreover, the 5-year OS rate for patients with mGPS=1 
was better than patients with mGPS=2 (74.1% vs. 54.7%, 
p=0.036). The OS rate was significantly worse in elderly 
patients and patients with poor PS, increased LDH, multiple 
ent mGPS (Table 1). No significant difference in the inci-
dence of comorbidities associated with elevated CRP levels, 
such as chronic hepatitis B, diabetes, and cardiovascular dis-
ease (except hypertension) existed among the three groups. 
However, mean serum CRP levels were comparable among 
patients with hypertension versus patients without hyperten-
sion (mean±SD, 19.93±34.80 mg/L vs. 12.43±30.11 mg/L, 
p=0.084) (data not shown).
Treatment modalities and response
The primary treatment modalities were as follows: 49 cases 
(17.2%) received chemotherapy followed by radiotherapy, 
182 cases (63.9%) received chemotherapy alone, and 54 
cases (18.9%) received surgery (i.e., total or partial removal 
of apparent lymphoma) followed by chemotherapy (Table 
2). No significant differences were found in the treatment 
modalities according to mGPS (p=0.162).
The responses to R-CHOP therapy are summarized in Ta-
ble 2. The median number of cycles of R-CHOP therapy 
was 6 (range, 3‒8 cycles). The median response duration 
was 39.1 months (range, 28.5‒49.8 months). The responses 
after 3 cycles of R-CHOP therapy were evaluated in 261 pa-
tients, and the CR rate was 55.1%. CR rates inpatients with 
mGPS=0, mGPS=1, and mGPS=2 were 53.8% (119/204), 
33.3% (19/57), and 25.0% (6/24), respectively. The CR rate 
in response to 3 cycles of R-CHOP therapy in patients with 
mGPS=2 group was significantly lower compared to pa-
tients in the other groups (p=0.001). In univariate analyses, 
older age (>60 years) (p=0.006), bulky disease (largest di-
ameter of the disease ≥10 cm) (p=0.001), ≥2 EN involved 
Table 2. Response to R-CHOP Therapy According to mGPS Level
Characteristics
Total
n=285 (%)
mGPS=0
n=204 (%)
mGPS=1
n=57 (%)
mGPS=2
n=24 (%)
p value
Treatment modalities, n (%) 0.162
    CT alone 182 (63.9) 128 (62.7) 36 (63.2) 18 (75.0)
    CT followed by RT   49 (17.2)   34 (16.7) 10 (17.5)   5 (20.8)
    Surgery followed by CT   54 (18.9)   42 (20.6) 11 (19.3) 1 (4.2)
No. of R-CHOP cycles, median    6 (3‒8)    6 (3‒8)  6 (3‒8)  6 (3‒8) 0.293
Response after 3 cycles, n (%)*
    No. of patients 261 204 57 24
    CR/PR 144 (55.1)/110 (42.1) 119 (53.8)/75 (36.8) 19 (33.3)/34 (59.6) 6 (25.0)/1 (4.2) 0.001
    Relapse disease or PD   7 (2.6)   4 (2.0) 2 (3.5) 1 (4.2)
Response after ≥6 cycles, n (%)*
    No. of patients 207 (72.6) 145 (71.1) 45 (78.9) 17 (70.8) 0.489
    CR/PR 163 (78.7)/30 (14.5) 122 (84.1)/16 (11.0) 31 (68.9)/10 (22.2) 10 (58.8)/4 (23.5) 0.168
    Relapse disease or PD   4 (1.9)   2 (1.4) 1 (2.2) 1 (5.9)
mGPS, modified Glasgow Prognostic Score; CT, chemotherapy; RT, radiotherapy; CR, complete response; PR, partial response; PD, progressive disease.
*Response to treatment were categorized as defined by Cheson, et al.17
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Table 3. Univariate Analyses Based on CR Rate and Survival
Factors
CR rate* OS PFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age >60 yrs 0.508 (0.313‒0.824) 0.006 2.252 (1.338‒3.791) 0.002 1.681 (1.036‒2.728) 0.035
Gender, male 0.854 (0.531‒1.373) 0.514 1.036 (0.624‒1.720) 0.893 0.960 (0.593‒1.554) 0.867
ECOG ≥2 0.813 (0.320‒2.068) 0.664 3.026 (1.533‒5.974) 0.001 1.907 (0.871‒4.177) 0.107
B symptoms 0.582 (0.303‒1.120) 0.105 1.617 (0.875‒2.990) 0.125 1.803 (1.014‒3.205) 0.045
Mass ≥10 cm 0.367 (0.207‒0.652) 0.001 1.552 (0.901‒2.675) 0.113 1.063 (0.606‒1.865) 0.831
EN sites ≥2 0.384 (0.232‒0.636) <0.001 2.391 (1.293‒4.423) 0.005 1.510 (0.899‒2.537) 0.119
BM involve 0.700 (0.306‒1.604) 0.400 2.074 (1.017‒4.230) 0.045 1.960 (0.967‒3.973) 0.062
Stage III/IV 0.502 (0.396‒0.637) <0.001 4.533 (2.482‒8.278) <0.001 3.663 (2.150‒6.239) <0.001
LDH >245 U/L 0.372 (0.213‒0.651) 0.001 1.296 (0.708‒2.372) 0.400 1.518 (0.839‒2.747) 0.168
ALC <1.0×109/L 1.649 (1.024‒2.656) 0.039 0.340 (0.192‒0.603) <0.001 0.615 (0.377‒1.003) 0.051
IPI score ≥2 0.211 (0.125‒0.354) <0.001   7.195 (3.269‒15.836) <0.001 3.453 (1.940‒6.148) <0.001
mGPS ≥2 0.428 (0.281‒0.651) <0.001 3.371 (1.698‒6.689) 0.001 1.453 (1.020‒2.069) 0.089
CR, complete response; OS, overall survival; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; EN, extranodal; BM, bone mar-
row; LDH, lactate dehydrogenase; ALC, absolute lymphocyte count; IPI, International Prognostic Index; mGPS, modified Glasgow Prognostic Score; HR, 
hazard ratio; CI, confidence interval.         
*CR rate compared to 3 cycles of R-CHOP therapy.
Table 4. Multivariate Analyses on CR Rate and Survival
Factors
CR rate* OS PFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age >60 yrs 0.470 (0.262‒0.842) 0.011 2.724 (1.633‒4.543) 0.001 1.545 (0.906‒2.635) 0.110
ECOG ≥2 1.584 (0.805‒3.118) 0.183
B symptoms 1.336 (0.719‒2.482) 0.359
Mass ≥10 cm 0.417 (0.209‒0.833) 0.013
EN sites ≥2 0.808 (0.434‒1.503) 0.512 1.216 (0.628‒2.354) 0.562
BM involve 0.929 (0.479‒1.800) 0.827
Stage III/IV 0.387 (0.209‒0.719) 0.003 2.684 (1.445‒4.958) 0.002 2.978 (1.403‒6.321) 0.004
LDH >245 U/L 0.532 (0.271‒1.046) 0.067
ALC <1.0×109/L 0.709 (0.358‒1.403) 0.323 0.477 (0.286‒0.797) 0.005
mGPS ≥2 0.612 (0.380‒0.988) 0.044 1.308 (0.780‒2.196) 0.037
CR, complete response; OS, overall survival; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; EN, extranodal; BM, bone mar-
row; LDH, serum lactate dehydrogenase level; ALC, absolute lymphocyte count; mGPS, modified Glasgow Prognostic Score; HR, hazard ratio; CI, confi-
dence interval.      
*CR rate compared to 3 cycles of R-CHOP therapy.
Fig. 1. Kaplan-Meier curves of overall survival and progression-free survival comparisons. (A) Overall survival and (B) progression-free survival according to 
mGPS levels in DLBCL patients treated with the R-CHOP regimen. mGPS, modified Glasgow Prognostic Score; DLBCL, diffuse large B cell lymphoma.
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is not limited to solid tumors but also shapes the biological 
characteristics of B-cell lymphoma, including DLBCL.23,24
CRP is a member of the class of acute-phase reactants, 
and due to its sensitivity, specificity, and reproducibility in 
hospital laboratories, is commonly used to assess the magni-
tude of the systemic inflammatory response. Elevated CPR 
concentration has prognostic value in gastrointestinal, uri-
nary, bladder, pancreas, renal, and lung cancer,9 as well 
aslymphoma.13 CRP synthesis in liver is promoted by several 
proinflammatory cytokines, including interleukin-1, tumor 
necrosis factor-1, and interleukin-6 (IL-6).25-27 IL-6 plays an 
important role in the pathogenesis of lymphoma and is an in-
dependent indicator of long-term outcome in NHL.28-30 Eval-
uation of serum CRP levels constitutes a powerful and inter-
esting biomarker to evaluate inflammatory prognostic factors 
that appear to be associated with IL-6.13,31
There was a negative correlation between CRP and albu-
min levels in cancer patients, reflecting both systemic in-
flammation and the amount of lean tissue.9,32 Loss of lean 
tissue in cancer patients has been recognized to result in 
poor performance status.32 Poor performance status (ECOG 
PS ≥2) was one of five factors in the IPI score.3
Our study showed that regarding the response to therapy 
and survival outcome, high mGPS was associated with poor 
prognostic factors including older age (>60 years), multiple 
EN involved, advanced disease stage, and the presence of B 
symptoms. These results indicate that mGPS may reflect a 
tumor’s growth and invasive potential (tumor stage and 
number of EN sites), the patient’s response to the tumor 
(status for B symptoms), and the patient’s ability to tolerate 
intensive therapy (age). In this study, mGPS, bulky disease, 
and disease stage were shown to be significant prognostic 
parameters on the CR rate after 3 cycles of R-CHOP thera-
py. However, after 6 or more cycles of R-CHOP therapy, 
there was no significant difference in CR rate among each 
mGPS group. The comparable PFS according to mGPS 
may be explained by the result of comparable CR rates af-
ter 6 or more cycles of R-CHOP therapy. Consistent with 
previous studies,3,4,33,34 our results reveal that IPI score, age, 
and baseline ALC were predictive factors of OS. Addition-
ally, high mGPS was associated with inferior OS indepen-
dent of other prognostic factors (p=0.037). 
In the present study, patients with clinical evidence of 
acute infection or chronic active inflammatory disease that 
was associated with elevated CRP levels were excluded. 
There were no significant differences in the incidence of 
comorbidities that can increase serum CRP levels,15,16 such 
EN involvement sites, BM involvement, advanced stage, 
low ALC at diagnosis, unfavorable IPI, and mGPS ≥2 (Ta-
ble 3). Multivariate analyses for OS revealed that older age 
(HR=2.724; 95% CI, 1.633 to 4.543; p=0.001), advanced 
stage (HR=2.684; 95% CI, 1.445 to 4.958; p=0.002), lower 
ALC (HR=0.477; 95% CI, 0.286 to 0.797; p=0.005), and 
mGPS ≥2 (HR=1.308; 95% CI, 0.780 to 2.196; p=0.037) 
were independently associated with shorter OS.
Progression-free survival
The 5-year PFS rate was 76.1% in patients with mGPS=0, 
62.3% in patients with mGPS=1, and 66.4% in patients 
with mGPS=2. Patients with lower mGPS tended to have a 
longer PFS compared to those with higher mGPS, although 
it was statistically insignificant (p=0.112) (Fig. 1B, Table 
3). Patients with stage III or higher disease had inferior PFS 
compared to those with stage I or II disease (5-year PFS, 
84.4% vs. 59.2%; p<0.001), and disease stage was the only 
prognostic factor for PFS in Cox’s proportional hazard 
model (HR=2.978; 95% CI, 1.403 to 6.321; p=0.004). Al-
though patients who were older had B symptoms at diagno-
sis, or unfavorable IPI score showed a tendency of lower 
PFS (Table 3), stepwise multiple logistic regression analy-
ses did not identify any other independent prognostic fac-
tors for PFS (Table 4).
DISCUSSION
Since the introduction of the R-CHOP regimen, it has be-
come the standard treatment for patients with DLBCL.1,2 
However, this raises concerns regarding the utility of previ-
ously identified prognostic factors, such as the IPI. In large 
cohort studies, the systemic inflammatory response, as evi-
denced by the mGPS, is a powerful prognostic factor in pa-
tients with cancer. mGPS is simple to measure, routinely 
available, and well standardized worldwide.10,18 It also has 
been shown that the mGPS is an independent prognostic fac-
tor of survival outcome in extranodal NK/T-cell lymphoma, 
nasal type.14 In this study, we observed for the first time that 
mGPS was significantly associated with the response rate to 
R-CHOP therapy and survival outcomes in DLBCL patients 
treated with the R-CHOP regimen. 
B-cell lymphoma present as tumors with a variable in-
flammatory infiltrate that includes effector and regulatory T 
cells, macrophages, and dendrite cells.19-22 Recent studies 
demonstrate that the role of the host inflammatory response 
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sponse in predicting survival in patients with primary operable 
cancer. Future Oncol 2010;6:149-63. 
9. McMillan DC. Systemic inflammation, nutritional status and sur-
vival in patients with cancer. Curr Opin Clin Nutr Metab Care 
2009;12:223-6. 
10. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, 
O’Reilly DS, et al. A comparison of inflammation-based prognos-
tic scores in patients with cancer. A Glasgow Inflammation Out-
come Study. Eur J Cancer 2011;47:2633-41. 
11. Levens JM, Gordon J, Gregory CD. Micro-environmental factors 
in the survival of human B-lymphoma cells. Cell Death Differ 
2000;7:59-69.
12. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab 
I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-
Hodgkin’s lymphoma cells and act as cooperative growth factors. 
Cancer Res 1996;56:5499-505.
13. Suzuki K, Terui Y, Nishimura N, Mishima Y, Sakajiri S, Yokoya-
ma M, et al. Prognostic value of C-reactive protein, lactase dehy-
drogenase and anemia in recurrent or refractory aggressive lym-
phoma. Jpn J Clin Oncol 2013;43:37-44. 
14. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The 
Glasgow Prognostic Score (GPS) as a novel and significant pre-
dictor of extranodal natural killer/T-cell lymphoma, nasal type. 
Am J Hematol 2013;88:394-9. 
15. Gortney JS, Sanders RM. Impact of C-reactive protein on treat-
ment of patients with cardiovascular disease. Am J Health Syst 
Pharm 2007;64:2009-16.
16. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, et 
al. Association of C-reactive protein with type 2 diabetes: prospec-
tive analysis and meta-analysis. Diabetologia 2009;52:1040-7. 
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Con-
nors JM, et al. Report of an international workshop to standardize 
response criteria for non-Hodgkin’s lymphomas. NCI Sponsored 
International Working Group. J Clin Oncol 1999;17:1244.
18. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop 
DJ. Evaluation of cumulative prognostic scores based on the sys-
temic inflammatory response in patients with inoperable non-
small-cell lung cancer. Br J Cancer 2003;89:1028-30.
19. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui 
JD, et al. A critical function for type I interferons in cancer immu-
noediting. Nat Immunol 2005;6:722-9. 
20. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and 
cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
21. Morse HC 3rd, Kearney JF, Isaacson PG, Carroll M, Fredrickson 
TN, Jaffe ES. Cells of the marginal zone--origins, function and 
neoplasia. Leuk Res 2001;25:169-78.
22. Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, 
Thompson KM, et al. Lymphomas can develop from B cells 
chronically helped by idiotype-specific T cells. J Exp Med 2007; 
204:1181-91.
23. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, 
Rigal D, et al. Interleukin-10 gene promoter polymorphisms influ-
ence the clinical outcome of diffuse large B-cell lymphoma. Blood 
2004;103:3529-34.
24. Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, 
Coiffier B, et al. Elevated IL-10 plasma levels correlate with poor 
prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 
2006;17:60-6.
25. Balkwill F, Mantovani A. Inflammation and cancer: back to Vir-
chow? Lancet 2001;357:539-45.
as chronic hepatitis B, diabetes, and cardiovascular disease 
(except hypertension) among mGPS groups. However, the 
mean value of serum CRP levels was comparable among 
patients with hypertension compared to those without hy-
pertension (mean±SD, 19.93±34.80 mg/L vs. 12.43±30.11 
mg/L, p=0.084). 
In conclusion, to our knowledge, we have demonstrated 
for the first time that mGPS can be considered a potential 
prognostic factor that may predict early responses to R-
CHOP therapy in DLBCL patients. We also demonstrated 
mGPS can predict overall survival in patients with DLBCL 
treated with the R-CHOP regimen. These findings may be 
clinically useful for predicting survival outcomes in DLB-
CL. A more accurate assessment would be likely if mGPS 
is combined with other prognostic factors. Additional pro-
spective studies are needed to confirm the clinical potential 
of mGPS as prognostic factor in DLBCL. 
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